Dementia Drugs
Dementia drugs, particularly for Alzheimer's Disease, focus on symptom management rather than cure. Cholinesterase inhibitors like donepezil, rivastigmine, and galantamine enhance brain function by boosting acetylcholine levels, crucial for memory and learning. Another medication, memantine, an NMDA receptor antagonist, helps regulate glutamate activity, addressing symptoms such as confusion and memory loss. While these drugs can temporarily improve cognitive function and quality of life, they do not stop the progression of the disease. Ongoing research seeks to identify new therapeutic targets and more effective treatments that could potentially alter the course of dementia in the future.
Committee Members
Jacqueline Tuppen
Cogs Club, United Kingdom
Yong Xiao Wang
Albany Medical College, United States
Kaoru Sakatani
The University of Tokyo, Japan Dementia 2023 Speakers
Suren A Tatulian
University of Central Florida, United States
Constantina Mizis
The Latino Alzheimer’s and Memory Disorders Alliance, United States
Paul Y Song
NKGen Biotech, United States
Marco Ruggiero
Silver Spring Sagl, Switzerland
Title : Cerebral vascular calcium signaling in diabetic alzheimer's disease-related dementias
Yong Xiao Wang, Albany Medical College, United States
Title : Deep learning-based risk assessment of cognitive impairment using health examination data
Kaoru Sakatani, The University of Tokyo, Japan
Title : Evaluation of the neuroprotective potential of indicaxanthin from opuntia ficus indica fruit against dysmetabolism-related neurodegeneration both in vivo and in vitro
Mario Allegra, University of Palermo, Italy
Title : Cogs Club: Making a difference
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Development of imaging based biomarkers for neurovascular abnormalities in neurodegenerative diseases
Jun Hua, Johns Hopkins University School of Medicine, United States
Title : Psychosocial considerations in management of corticobasal degeneration
Esraa Askar, Forest Hills Hospital, United States